BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9917095)

  • 1. Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells.
    Mezzanzanica D; Canevari S; Mazzoni A; Figini M; Colnaghi MI; Waks T; Schindler DG; Eshhar Z
    Cancer Gene Ther; 1998; 5(6):401-7. PubMed ID: 9917095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells.
    Scherf U; Benhar I; Webber KO; Pastan I; Brinkmann U
    Clin Cancer Res; 1996 Sep; 2(9):1523-31. PubMed ID: 9816329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity.
    Moritz D; Groner B
    Gene Ther; 1995 Oct; 2(8):539-46. PubMed ID: 8593604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors.
    Scott AM; Geleick D; Rubira M; Clarke K; Nice EC; Smyth FE; Stockert E; Richards EC; Carr FJ; Harris WJ; Armour KL; Rood J; Kypridis A; Kronina V; Murphy R; Lee FT; Liu Z; Kitamura K; Ritter G; Laughton K; Hoffman E; Burgess AW; Old LJ
    Cancer Res; 2000 Jun; 60(12):3254-61. PubMed ID: 10866319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
    Hwu P; Yang JC; Cowherd R; Treisman J; Shafer GE; Eshhar Z; Rosenberg SA
    Cancer Res; 1995 Aug; 55(15):3369-73. PubMed ID: 7614473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression, structure prediction and functional analysis of murine single-chain fragment variable antibody against human cervical cancer].
    Wang Y; Li X; Chen W
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jan; 26(1):16-21. PubMed ID: 16495168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunolabeling of CD3-positive lymphocytes with a recombinant single-chain antibody/alkaline phosphatase conjugate.
    Bourin P; Servat A; Lataillade JJ; Goyffon M; Vaux D; Billiald P
    Biol Chem; 2000 Feb; 381(2):173-8. PubMed ID: 10746749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression.
    Altenschmidt U; Klundt E; Groner B
    J Immunol; 1997 Dec; 159(11):5509-15. PubMed ID: 9548491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo.
    Schirrmann T; Pecher G
    Cancer Gene Ther; 2002 Apr; 9(4):390-8. PubMed ID: 11960290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetically targeted T cells eradicate established breast cancer in syngeneic mice.
    Wang H; Wei H; Zhang R; Hou S; Li B; Qian W; Zhang D; Kou G; Dai J; Guo Y
    Clin Cancer Res; 2009 Feb; 15(3):943-50. PubMed ID: 19188165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen.
    Sahagan BG; Dorai H; Saltzgaber-Muller J; Toneguzzo F; Guindon CA; Lilly SP; McDonald KW; Morrissey DV; Stone BA; Davis GL
    J Immunol; 1986 Aug; 137(3):1066-74. PubMed ID: 3088107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
    Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum.
    Westwood JA; Murray WK; Trivett M; Haynes NM; Solomon B; Mileshkin L; Ball D; Michael M; Burman A; Mayura-Guru P; Trapani JA; Peinert S; Hönemann D; Miles Prince H; Scott AM; Smyth MJ; Darcy PK; Kershaw MH
    J Immunother; 2009 Apr; 32(3):292-301. PubMed ID: 19242371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma.
    Gonzalez S; Naranjo A; Serrano LM; Chang WC; Wright CL; Jensen MC
    J Gene Med; 2004 Jun; 6(6):704-11. PubMed ID: 15170741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteins.
    Myers KA; Ryan MG; Stern PL; Shaw DM; Embleton MJ; Kingsman SM; Carroll MW
    Cancer Gene Ther; 2002 Nov; 9(11):884-96. PubMed ID: 12386827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The T-body approach: redirecting T cells with antibody specificity.
    Eshhar Z
    Handb Exp Pharmacol; 2008; (181):329-42. PubMed ID: 18071952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor.
    Pameijer CR; Navanjo A; Meechoovet B; Wagner JR; Aguilar B; Wright CL; Chang WC; Brown CE; Jensen MC
    Cancer Gene Ther; 2007 Jan; 14(1):91-7. PubMed ID: 17024231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multivalent antibody fragments with high functional affinity for a tumor-associated carbohydrate antigen.
    Rheinnecker M; Hardt C; Ilag LL; Kufer P; Gruber R; Hoess A; Lupas A; Rottenberger C; Plückthun A; Pack P
    J Immunol; 1996 Oct; 157(7):2989-97. PubMed ID: 8816407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sheep red blood cells armed with anti-CD20 single-chain variable fragments (scFvs) fused to a glycosylphosphatidylinositol (GPI) anchor: a strategy to target CD20-positive tumor cells.
    Hamdy N; Goustin AS; Desaulniers JP; Li M; Chow CS; Al-Katib A
    J Immunol Methods; 2005 Feb; 297(1-2):109-24. PubMed ID: 15777935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A human monoclonal antimelanoma single-chain Fv antibody derived from tumor-infiltrating lymphocytes.
    Zhang H; Lake DF; Barbuto JA; Bernstein RM; Grimes WJ; Hersh EM
    Cancer Res; 1995 Aug; 55(16):3584-91. PubMed ID: 7627967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.